| Name | Nina Geiger |
| Affiliation | Intitute of System Immunology
Chair of System Immunology II |
| Street | Versbacher Str. 9 |
| Zip Code | 97078 |
| City | Würzburg |
| Email | E-mail |
| Telephone | +49 931 31- 85765 |
| Homepage | |
| Section | Infection & Immunity |
| Title of Thesis Project | Defining Newly Emerging Roles for the Influenza A Virus Nuclear Export Protein |
| Primary Supervisor | Dr. Simone Backes |
| Member of Thesis Committee | Jun.-Prof. Dr. Redmond Smyth |
| Prof. Dr. Dorothee Viemann |
| |
| Conference Contribution | |
|
Publication Personal Formatting |
|
Geiger, N: Charakterisierung des Wirkmechanismus von Selektiven Serotonin-Wiederaufnahme-Inhibitoren (SSRI) bei Infektion mit SARS-CoV-2., Springer Spektrum Wiesbaden, 2023, 978-3-658-43070-2.
|
|
Drug-induced phospholipidosis is not correlated with the inhibition of SARS-CoV-2 - inhibition of SARS-CoV-2 is cell line-specific. Diesendorf V, Roll V, Geiger N, Fähr S, Obernolte H, Sewald K, Bodem J. Front Cell Infect Microbiol. 2023 Aug 11;13:1100028. doi: 10.3389/fcimb.2023.1100028. eCollection 2023.
|
|
Korupensamine A, but not its atropisomer, korupensamine B, inhibits SARS-CoV-2 in vitro by targeting its main protease (Mpro). Sayed AM, Ibrahim AH, Tajuddeen N, Seibel J, Bodem J, Geiger N, Striffler K, Bringmann G, Abdelmohsen UR. Eur J Med Chem. 2023 May 5;251:115226. doi: 10.1016/j.ejmech.2023.115226. Epub 2023 Feb 28.
|
|
Azido-Ceramides, a Tool to Analyse SARS-CoV-2 Replication and Inhibition-SARS-CoV-2 Is Inhibited by Ceramides. Brenner D, Geiger N, Schlegel J, Diesendorf V, Kersting L, Fink J, Stelz L, Schneider-Schaulies S, Sauer M, Bodem J, Seibel J. Int J Mol Sci. 2023 Apr 14;24(8):7281. doi: 10.3390/ijms24087281.
|
|
Cell Type-Specific Anti-Viral Effects of Novel SARS-CoV-2 Main Protease Inhibitors. Geiger N, Diesendorf V, Roll V, König EM, Obernolte H, Sewald K, Breidenbach J, Pillaiyar T, Gütschow M, Müller CE, Bodem J. Int J Mol Sci. 2023 Feb 16;24(4):3972. doi: 10.3390/ijms24043972.
|
|
Acetylsalicylic Acid and Salicylic Acid Inhibit SARS-CoV-2 Replication in Precision-Cut Lung Slices. Geiger N, König EM, Oberwinkler H, Roll V, Diesendorf V, Fähr S, Obernolte H, Sewald K, Wronski S, Steinke M, Bodem J. Vaccines (Basel). 2022 Sep 27;10(10):1619. doi: 10.3390/vaccines10101619.
|
|
The Acid Ceramidase Is a SARS-CoV-2 Host Factor. Geiger N, Kersting L, Schlegel J, Stelz L, Fähr S, Diesendorf V, Roll V, Sostmann M, König EM, Reinhard S, Brenner D, Schneider-Schaulies S, Sauer M, Seibel J, Bodem J. Cells. 2022 Aug 15;11(16):2532. doi: 10.3390/cells11162532.
|
|
Selection and Validation of siRNAs Preventing Uptake and Replication of SARS-CoV-2. Friedrich M, Pfeifer G, Binder S, Aigner A, Vollmer Barbosa P, Makert GR, Fertey J, Ulbert S, Bodem J, König EM, Geiger N, Schambach A, Schilling E, Buschmann T, Hauschildt S, Koehl U, Sewald K. Front Bioeng Biotechnol. 2022 Mar 2;10:801870. doi: 10.3389/fbioe.2022.801870. eCollection 2022.
|
|
The blood-brain barrier is dysregulated in COVID-19 and serves as a CNS entry route for SARS-CoV-2. Krasemann S, Haferkamp U, Pfefferle S, Woo MS, Heinrich F, Schweizer M, Appelt-Menzel A, Cubukova A, Barenberg J, Leu J, Hartmann K, Thies E, Littau JL, Sepulveda-Falla D, Zhang L, Ton K, Liang Y, Matschke J, Ricklefs F, Sauvigny T, Sperhake J, Fitzek A, Gerhartl A, Brachner A, Geiger N, König EM, Bodem J, Franzenburg S, Franke A, Moese S, Müller FJ, Geisslinger G, Claussen C, Kannt A, Zaliani A, Gribbon P, Ondruschka B, Neuhaus W, Friese MA, Glatzel M, Pless O. Stem Cell Reports. 2022 Feb 8;17(2):307-320. doi: 10.1016/j.stemcr.2021.12.011. Epub 2022 Jan 20.
|
|
Targeting the Main Protease of SARS-CoV-2: From the Establishment of High Throughput Screening to the Design of Tailored Inhibitors. Breidenbach J, Lemke C, Pillaiyar T, Schäkel L, Al Hamwi G, Diett M, Gedschold R, Geiger N, Lopez V, Mirza S, Namasivayam V, Schiedel AC, Sylvester K, Thimm D, Vielmuth C, Phuong Vu L, Zyulina M, Bodem J, Gütschow M, Müller CE. Angew Chem Int Ed Engl. 2021 Apr 26;60(18):10423-10429. doi: 10.1002/anie.202016961. Epub 2021 Mar 24.
|
|
The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue. Zimniak M, Kirschner L, Hilpert H, Geiger N, Danov O, Oberwinkler H, Steinke M, Sewald K, Seibel J, Bodem J. Sci Rep. 2021 Mar 15;11(1):5890. doi: 10.1038/s41598-021-85049-0.
|
|
| | Last update Publications 08.08.2024 |
|